News

The KARDIA-1 Phase 2 trial is a randomized, double-blind (DB), placebo-controlled, multi-center global dose-ranging study designed to evaluate the efficacy and safety of zilebesiran as monotherapy in adults with mild-to-moderate hypertension.

Among people with type 1 and type 2 diabetes, being divorced is associated with a two-thirds higher risk of lower limb amputation (LLA) (amputations below the knee level) compared with being married, and being male is associated with a 57%...

“If blood pressure is only measured while people are seated upright, cardiovascular disease risk may be missed if not measured also while they are lying supine on their backs,” said lead study author Duc M. Giao.

The Business Essentials for Cardiovascular Fellows Program focuses on the non-clinical competencies of healthcare operations, economics, change leadership and people management. 

A recent study from Mayo Clinic finds that exercise test abnormalities, such as low functional aerobic capacity, predicted non-cardiovascular death in addition to cardiovascular-related deaths.

The latest WATCHMAN FLX Pro device is enhanced with a coating designed to reduce device-related thrombus and enable faster, controlled healing and endothelization of the device surface.

New York, NY – The Icahn School of Medicine at Mount Sinai announced that it has signed a memorandum of understanding with the Brazilian Clinical Research Institute (BCRI) to focus on advancing cardiovascular disease research, innovation, and...

"The results show both that the red blood cells convey protection against injury in the heart in the event of low oxygen levels, and how that protection can be enhanced through a simple dietary advice. This may be of great importance for...

Cedars-Sinai investigators have shown that redo transcatheter aortic valve replacement (TAVR) procedures are both safe and effective when compared with situations in which patients with similar risk profiles undergo the same procedure for the...

Ohio State’s Richard M. Ross Heart Hospital will continue to recruit patients in the randomized, double blinded study (ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System [ALT-FLOW II]).